|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 93 No. 8 (April 15), 1999:
pp. 2491-2501
A Randomized Phase 3 Study of Peripheral Blood Progenitor Cell
Mobilization With Stem Cell Factor and Filgrastim in High-Risk Breast
Cancer Patients
Elizabeth J. Shpall,
Catherine A. Wheeler,
Stewart A. Turner,
Saul Yanovich,
Randy A. Brown,
Andrew L. Pecora,
Thomas C. Shea,
Kenneth
F. Mangan,
Stephanie F. Williams,
C. Fred LeMaistre,
Gwynn D. Long,
Roy Jones,
Mark W. Davis,
Robyn Murphy-Filkins,
William R.L. Parker, and
John A. Glaspy
From the Bone Marrow Transplant Programs, University of Colorado
Health Sciences Center, Denver, CO; Beth Israel Hospital/Dana-Farber
Cancer Institute, Boston, MA; Amgen Inc, Thousand Oaks, CA; Medical
College of Virginia Hospitals, Richmond, VA; Washington University
School of Medicine, St Louis, MO; Hackensack University Medical Center,
Hackensack, NJ; UNC Lineburger Cancer Center, Chapel Hill, NC; The
Temple University Cancer Center, Philadelphia, PA; the University of
Chicago Medical Center, Chicago, IL; South Texas Cancer Institute, San
Antonio, TX; Stanford Medical Center, Stanford, CA; and Bowyer Oncology
Center, UCLA School of Medicine, Los Angeles, CA.
This randomized study compared the number of leukaphereses required
to collect an optimal target yield of 5 × 106
CD34+ peripheral blood progenitor cells/kg, using either
stem cell factor (SCF) at 20 µg/kg/d in combination with Filgrastim
at 10 µg/kg/d or Filgrastim alone at 10 µg/kg/d, from 203 patients
with high-risk stage II, III, or IV breast cancer. Leukapheresis began on day 5 of cytokine administration and continued daily until the
target yield of CD34+ cells had been reached or a maximum
of 5 leukaphereses performed. By day 5 of leukapheresis, 63% of the
patients treated with SCF plus Filgrastim (n = 100) compared with
47% of those receiving Filgrastim alone (n = 103) reached the
CD34+ cell target yield. There was a clinically and
statistically significant reduction (P < .05) in the number
of leukaphereses required to reach the target yield for the patients
receiving SCF plus Filgrastim (median, 4 leukaphereses) compared with
patients receiving Filgrastim alone (median, 6 or more leukapherses;
ie, <50% of patients reached the target in 5 leukaphereses). All
patients receiving SCF were premedicated with antihistamines,
albuterol, and pseudoephedrine. Treatment was safe, generally well
tolerated, and not associated with life-threatening or fatal toxicity.
In conclusion, SCF plus Filgrastim is a more effective peripheral blood
progenitor cell (PBPC)-mobilization regimen than Filgrastim alone. In
addition to the potential for reduced leukapheresis-related morbidity
and costs, SCF offers additional options for obtaining cells for
further graft manipulation.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Gabbianelli, O. Morsilli, A. Massa, L. Pasquini, P. Cianciulli, U. Testa, and C. Peschle
Effective erythropoiesis and HbF reactivation induced by kit ligand in -thalassemia
Blood,
January 1, 2008;
111(1):
421 - 429.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Carlo-Stella, M. Di Nicola, P. Longoni, L. Cleris, C. Lavazza, R. Milani, M. Milanesi, M. Magni, V. Pace, F. Colotta, et al.
Placental Growth Factor-1 Potentiates Hematopoietic Progenitor Cell Mobilization Induced by Granulocyte Colony-Stimulating Factor in Mice and Nonhuman Primates
Stem Cells,
January 1, 2007;
25(1):
252 - 261.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Carlo-Stella, M. Di Nicola, R. Milani, A. Guidetti, M. Magni, M. Milanesi, P. Longoni, P. Matteucci, F. Formelli, F. Ravagnani, et al.
Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers
Blood,
May 1, 2004;
103(9):
3287 - 3295.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Zeuner, F. Pedini, M. Signore, U. Testa, E. Pelosi, C. Peschle, and R. De Maria
Stem cell factor protects erythroid precursor cells from chemotherapeutic agents via up-regulation of BCL-2 family proteins
Blood,
July 1, 2003;
102(1):
87 - 93.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Hematti, S. E. Sellers, B. A. Agricola, M. E. Metzger, R. E. Donahue, and C. E. Dunbar
Retroviral transduction efficiency of G-CSF+SCF-mobilized peripheral blood CD34+ cells is superior to G-CSF or G-CSF+Flt3-L-mobilized cells in nonhuman primates
Blood,
March 15, 2003;
101(6):
2199 - 2205.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. F. Zhong, Y. Zhan, W. F. Anderson, and Y. Zhao
Murine hematopoietic stem cell distribution and proliferation in ablated and nonablated bone marrow transplantation
Blood,
November 15, 2002;
100(10):
3521 - 3526.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Carlo-Stella, M. Di Nicola, M. Magni, P. Longoni, M. Milanesi, C. Stucchi, L. Cleris, F. Formelli, and M. A. Gianni
Defibrotide in Combination with Granulocyte Colony-stimulating Factor Significantly Enhances the Mobilization of Primitive and Committed Peripheral Blood Progenitor Cells in Mice
Cancer Res.,
November 1, 2002;
62(21):
6152 - 6157.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Hess, K. D. Levac, F. N. Karanu, M. Rosu-Myles, M. J. White, L. Gallacher, B. Murdoch, M. Keeney, P. Ottowski, R. Foley, et al.
Functional analysis of human hematopoietic repopulating cells mobilized with granulocyte colony-stimulating factor alone versus granulocyte colony-stimulating factor in combination with stem cell factor
Blood,
July 18, 2002;
100(3):
869 - 878.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Mink and J. O. Armitage
High-Dose Therapy in Lymphomas: A Review of the Current Status of Allogeneic and Autologous Stem Cell Transplantation in Hodgkin's Disease and Non-Hodgkin's Lymphoma
Oncologist,
June 1, 2001;
6(3):
247 - 256.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. F. Duarte and D. A. Frank
SCF and G-CSF lead to the synergistic induction of proliferation and gene expression through complementary signaling pathways
Blood,
November 15, 2000;
96(10):
3422 - 3430.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. McNiece, R. Jones, S. I. Bearman, P. Cagnoni, Y. Nieto, W. Franklin, J. Ryder, A. Steele, J. Stoltz, P. Russell, et al.
Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer
Blood,
November 1, 2000;
96(9):
3001 - 3007.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Paquette, S. T. Dergham, E. Karpf, H.-J. Wang, D. J. Slamon, L. Souza, and J. A. Glaspy
Ex vivo expanded unselected peripheral blood: progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancer
Blood,
October 1, 2000;
96(7):
2385 - 2390.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
